Bcl-2 expression as an apoptotic index in non small cell lung carcinomas.
To evaluate the bcl-2 protein expression in non small cell lung carcinomas (NSCLC) as an index of apoptosis of these tumors, in fine needle aspiration biopsies (FNABs) of the lung, we studied thirty-eight cases of NSCLC (25 bronchogenic adenocarcinomas and 13 squamous. carcinomas. Bcl-2 protein was used as the primary antibody (monoclonal, DAKO) by Alkaline-phosphatase method. Very light haematoxylin was performed as the counterstain. The results were compared and confirmed histologically. A cytoplasmatic expression of the bcl-2 protein was found in 72% (18 out of 15) of the bronchogenic adenocarcinomas while 61.54% (8 out of 13) of squamous carcinomas showed bcl-2 expression. For the quantitative analysis of our results, we used the t-test and the difference between those two histologic types was regarded as statistically significant with p < 0.001.
Kalogeraki
A
A
Department of Pathology, Medical School, University of Crete, P.O. Box 1393, TT 71110, Heraklion, Crete, Greece.
Kozoni
V
V
Zoras
O
O
Tamiolakis
D
D
Panayiotides
J
J
Charakidas
A
A
Chalkiadakis
G
G
Bouros
D
D
Stathopoulos
E
E
Delides
G S
GS
D000230:Adenocarcinoma / Q000473:pathology; D000911:Antibodies, Monoclonal; D017209:Apoptosis; D001707:Biopsy, Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000096:biosynthesis / Q000276:immunology
D000911:Antibodies, Monoclonal; D019253:Proto-Oncogene Proteins c-bcl-2